These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36624153)

  • 21. Recap of FDA product approvals--1999.
    Miller JL
    Am J Health Syst Pharm; 2000 Mar; 57(5):418, 421-2. PubMed ID: 10711519
    [No Abstract]   [Full Text] [Related]  

  • 22. Fresh from the biotech pipeline-2018.
    Morrison C
    Nat Biotechnol; 2019 Feb; 37(2):118-123. PubMed ID: 30718867
    [No Abstract]   [Full Text] [Related]  

  • 23. Mammalian cell cultures for biologics manufacturing.
    Kantardjieff A; Zhou W
    Adv Biochem Eng Biotechnol; 2014; 139():1-9. PubMed ID: 24258145
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The rise (and decline?) of biotechnology.
    Kinch MS
    Drug Discov Today; 2014 Nov; 19(11):1686-1690. PubMed ID: 24747562
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative effectiveness research and the regulation of drugs, biologics and devices.
    Woodcock J
    J Comp Eff Res; 2013 Mar; 2(2):95-7. PubMed ID: 24236548
    [No Abstract]   [Full Text] [Related]  

  • 26. Switching Between Biologics and Biosimilars in Inflammatory Bowel Disease.
    Raffals LE; Nguyen GC; Rubin DT
    Clin Gastroenterol Hepatol; 2019 Apr; 17(5):818-823. PubMed ID: 30196164
    [No Abstract]   [Full Text] [Related]  

  • 27. Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019.
    Dhodapkar M; Zhang AD; Puthumana J; Downing NS; Shah ND; Ross JS
    JAMA Netw Open; 2021 Jun; 4(6):e2113224. PubMed ID: 34110392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Pharmaceutical Industry in 2022: An Analysis of FDA Drug Approvals from the Perspective of Molecules.
    de la Torre BG; Albericio F
    Molecules; 2023 Jan; 28(3):. PubMed ID: 36770706
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017.
    Zhang AD; Puthumana J; Downing NS; Shah ND; Krumholz HM; Ross JS
    JAMA Netw Open; 2020 Apr; 3(4):e203284. PubMed ID: 32315070
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 2010 FDA drug approvals.
    Mullard A
    Nat Rev Drug Discov; 2011 Feb; 10(2):82-5. PubMed ID: 21283092
    [No Abstract]   [Full Text] [Related]  

  • 31. Biotech drugs blaze a trail.
    Lawrence S
    Nat Biotechnol; 2006 Jul; 24(7):736. PubMed ID: 16841045
    [No Abstract]   [Full Text] [Related]  

  • 32. Biologics for inflammatory bowel disease: drug approval and monitoring in the United States.
    Tremaine WJ
    Gastroenterol Clin North Am; 2006 Dec; 35(4):735-41. PubMed ID: 17129810
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medipol: the guardian angel of biologics.
    Laue C; Ruppanner V
    Nanomedicine (Lond); 2006 Aug; 1(2):251-4. PubMed ID: 17716114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decisions hint that not all biologics are created with equal ease.
    Hutson S
    Nat Med; 2010 Nov; 16(11):1171. PubMed ID: 21052053
    [No Abstract]   [Full Text] [Related]  

  • 35. The year's new drugs and biologics 2018: Part II - News that shaped the industry in 2018.
    Graul AI; Dulsat C; Pina P; Cruces E; Tracy M
    Drugs Today (Barc); 2019 Feb; 55(2):131-160. PubMed ID: 30816887
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The year's new drugs & biologics, 2011.
    Graul AI; Cruces E; Dulsat C; Arias E; Stringer M
    Drugs Today (Barc); 2012 Jan; 48(1):33-77. PubMed ID: 22384459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Managing the expanded use of biologics across therapeutic areas: an example from b-cell targeted therapies.
    Cohen M; Morrow T; Penna P
    Am J Manag Care; 2006 Mar; 12(2 Suppl):S24-37; quiz S38. PubMed ID: 16551202
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015-2020.
    Arondekar B; Duh MS; Bhak RH; DerSarkissian M; Huynh L; Wang K; Wojciehowski J; Wu M; Wornson B; Niyazov A; Demetri GD
    Clin Cancer Res; 2022 Jan; 28(1):27-35. PubMed ID: 34667027
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How innovative technology is moving biologics into the 21st century.
    Robinson DK; Sethuraman N
    Clin Pharmacol Ther; 2010 Mar; 87(3):261-3. PubMed ID: 20160744
    [No Abstract]   [Full Text] [Related]  

  • 40. The challenge of follow-on biologics for treatment of multiple sclerosis.
    Rivera VM
    Neurology; 2010 Mar; 74(10):864. PubMed ID: 20211915
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.